Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes

American Journal of Physiology - Renal Physiology

Volumn 295, Issue 2, 2008, Pages

  Yuan, Hang ^a,b   Lanting, Linda ^a   Xu, Zhong Gao ^a,b   Li, Shu An ^a   Swiderski, Piotr ^a   Putta, Sumanth ^a   Jonnalagadda, Mahesh ^a   Kato, Mitsuo ^a   Natarajan, Rama ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Gene delivery

Indexed keywords

CHOLESTEROL; COLLAGEN TYPE 1; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; LIPOXYGENASE; LIPOXYGENASE 12; LIPOXYGENASE 15; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; MESSENGER RNA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GENE TARGETING; KIDNEY CORTEX; KIDNEY INJURY; MACROPHAGE; MALE; MONOCYTE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BODY WEIGHT; C57BL MOUSE; CELL CULTURE; CELL MOTION; DBA MOUSE; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; EXTRACELLULAR MATRIX; GLOMERULUS; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM;

ALBUMINURIA; ANIMALS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; BODY WEIGHT; CELL MOVEMENT; CELLS, CULTURED; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; KIDNEY GLOMERULUS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 52449107112     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90268.2008     Document Type: Article

References (51)

1. Adler S. Diabetic nephropathy: linking histology, cell biology, genetics. Kidney Int 66: 2095-2106, 2004.
2. Ardaillou R, Baud L, Sraer J. Lipoxygenase products and their functions in glomeruli. Adv Exp Med Biol 259: 49-74, 1989.
3. Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 58: 684-690, 2000.
4. Breyer MD, Bottinger E, Brosius 3rd FC, Coffman TM, Harris RC, Heilig CW, Sharma K. Mouse models of diabetic nephropathy. J Am Soc Nephrol 16: 27-45, 2005.
5. Cheng K, Ye Z, Guntaka RV, Mahato RI. Enhanced hepatic uptake and bioactivity of type α1(I) collagen gene promoter-specific triplex-forming oligonucleotides after conjugation with cholesterol. J Pharmacol Exp Ther 317: 797-805, 2006.
6. Chen M, Yang ZD, Smith KM, Carter JD, Nadler JL. Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity. Diabetologia 48: 486-495, 2005.
7. Czauderna F, Fechtner M, Dames S, Aygün H, Klippel A, Pronk GJ, Giese K, Kaufmann J. Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31: 2705-2716, 2003.
8. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443-453, 2007.
9. De PD, Bentley MV, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13: 431-456, 2007.
10. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001.
11. Funk CD. The molecular biology of mammalian lipoxygenase and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta 1304: 65-68, 1996.
12. Giunti S, Tesch GH, Pinach S, Burt DJ, Cooper ME, Cavallo-Perin P, Camussi G, Gruden G. Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 51: 198-207, 2008.
13. Guha M, Xu ZG, Tung D, Lanting L, Natarajan R. Specific downregulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 21: 3355-3368, 2007.
14. Gu JL, Natarajan R, Ben-Ezra J, Valente G, Scott S, Yoshimoto T, Yamamoto S, Rossi JJ, Nadler JL. Evidence that a porcine mononuclear type of 12-lipoxygenase is expressed and regulated in human adrenal glomerulosa cells. Endocrinology 134: 70-77, 1994.
15. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 431: 371-378, 2004.
16. Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, Takahashi T, Abe H, Iehara N, Fukatsu A, Okamoto H, Kita T, Doi T, Arai H. Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 360: 772-777, 2007.
17. Kang SW, Adler SG, Nast CC, LaPage J, Gu JL, Nadler JL, Natarajan R. 12-Lipoxygenase is increased in glucose-stimulated mesangial cells and in experimental diabetic nephropathy. Kidney Int 59: 1354-1362, 2001.
18. Kang SW, Natarajan R, Shahed A, Nast CC, LaPage J, Mundel P, Kashtan C, Adler SG. Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen 5 (IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. J Am Soc Nephrol 14: 3178-3187, 2003.
19. Katoh T, Lakkis FG, Makita N, Badr KF. Co-regulated expression of glomerular 12/15-lipoxygenase and interleukin-4 mRNAs in rat nephrotoxic nephritis. Kidney Int 46: 341-349, 1994.
20. Kato M, Yuan H, Xu ZG, Lanting L, Li SL, Wang M, Hu MC, Reddy MA, Natarajan R. Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J Am Soc Nephrol 17: 3325-3335, 2006.
21. Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ, Natarajan R. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA 104: 3432-3437, 2007.
22. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 8: 173-184, 2007.
23. Kim YS, Lanting L, Adler SG, Natarajan R. Differential behavior of mesangial cells derived from 12/15-lipoxygenase knockout mice relative to control mice. Kidney Int 64: 1702-1714, 2003.
24. Kim YS, Xu ZG, Reddy MA, Li SL, Lanting L, Sharma K, Adler SG, Natarajan R. Novel interactions between TGF-β1 actions and the 12/15-lipoxygenase pathway in mesangial cells. J Am Soc Nephrol 16: 352-362, 2005.
25. Kreisberg JI, Ayo SH. The glomerular mesangium in diabetes mellitus. Kidney Int 43: 109-111, 1993.
26. Kuan CJ, Al-Douahji M, Shankland SJ. The cyclin kinase inhibitor p21WAF1, CIP1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy. J Am Soc Nephrol 9: 986-993, 1998.
27. Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm KA. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 15: 2125-2138, 2004.
28. Li SL, Dwarakanath RS, Cai Q, Lanting L, Natarajan R. Effects of silencing leukocyte-type 12/15-lipoxygenase using short interfering RNAs. J Lipid Res 46: 220-229, 2005.
29. Matsusaka T, Xin J, Niwa S, Kobayashi K, Akatsuka A, Hashizume H, Wang QC, Pastan I, Fogo AB, Ichikawa I. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 16: 1013-1023, 2005.
30. Ma J, Natarajan R, LaPage J, Lanting L, Kim N, Becerra D, Clemmons B, Nast CC, Prakash GKS, Mandal M, Adler SG. 12/15-Lipoxygenase inhibitors in diabetic nephropathy in the rat. Prostaglandins Leukot Essent Fatty Acids 72: 13-20, 2005.
31. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007, 2005.
32. Munger KA, Montero A, Fukunaga M, Uda S, Yura T, Imai E, Kaneda Y, Valdivielso JM, Badr K. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function experimental glomerulonephritis. Proc Natl Acad Sci USA 96: 13375-13380, 1999.
33. Nadia AW, Benjamin S, Terry R, Roger MM. Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J Am Soc Nephrol 13: 2437-2445, 2002.
34. Natarajan R, Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol 24: 1542-1548, 2004.
35. Natarajan R, Bai W, Rangarajan V, Gonzales N, Gu JL, Lanting L, Nadler JL. Platelet-derived growth factor BB mediated regulation of 12-lipoxygenase in porcine aortic smooth muscle cells. J Cell Physiol 169: 391-400, 1996.
36. Natarajan R, Gonzales N, Lanting L, Nadler J. Role of the lipoxygenase pathway in angiotensin II-induced vascular smooth muscle cell hypertrophy. Hypertension 23: 142-147, 1994.
37. Natarajan R, Gu JL, Rossi J, Gonzales N, Lanting L, Xu L, Nadler J. Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. Proc Natl Acad Sci USA 90: 4947-4951, 1993.
38. Reddy MA, Adler SG, Kim YS, Lanting L, Rossi JJ, Kang SW, Nadler JL, Shahed A, Natarajan R. Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. Am J Physiol Renal Physiol 283: F985-F994, 2002.
39. Reddy MA, Thimmalapura PR, Lanting L, Nadler JL, Fatima S, Natarajan R. The oxidized lipid and lipoxygenase product 12(S)-hydroxyeicosatetraenoic acid induces hypertrophy and fibronectin transcription in vascular smooth muscle cells via p38 MAPK and cAMP response element binding protein activation. Mediation of angiotensin II effects. J Biol Chem 277: 9920-9928, 2002.
40. Rincon-Choles H, Kasinath BS, Gorin Y, Abboud HE. Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy. Kidney Int Suppl 82: 8-11, 2002.
41. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-beta as a key mediator. Diabetes 44: 1139-1146, 1995.
42. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178, 2004.
43. Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FY, Sourris KC, Penfold SA, Bach LA, Cooper ME, Forbes JM. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 57: 460-469, 2008.
44. Tsuchida K, Zhu Y, Siva S, Dunn SR, Sharma K. Role of Smad4 on TGF-beta-induced extracellular matrix stimulation in mesangial cells. Kidney Int 63: 2000-2009, 2003.
45. Vaziri ND, Xu ZG, Shahkarami A, Huang KT, Rodríguez-Iturbe B, Natarajan R. Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity. Kidney Int 68: 2787-2793, 2005.
46. Wen Y, Gu J, Vandenhoff GE, Liu X, Nadler JL. The role of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages. Am J Physiol Heart Circ Physiol 294: H1933-H1938, 2008.
47. Kip1, an inhibitor of cyclin-dependent kinases. Am J Pathol 158: 1091-1100, 2001.
48. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-β. Kidney Int 42: 647-656, 1992.
49. Xu ZG, Li SL, Lantin L, Kim YS, Shanmugam N, Reddy MA, Natarajan R. Relationship between 12/15-lipoxygenase and COX-2 in mesangial cells: potential role in diabetic nephropathy. Kidney Int 69: 512-519, 2006.
50. Yamamoto S. Mammalian lipoxygenase: molecular structures and functions. Biochim Biophys Acta 1128: 117-131, 1992.
51. Ziyadeh FN, Sharma K. Role of transforming growth factor-beta in diabetic glomerulosclerosis and renal hypertrophy. Kidney Int Suppl 51: S34-S36, 1995.